ATE496901T1 - Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung - Google Patents
Cannabinoidderivate, verfahren zu deren herstellung und deren verwendungInfo
- Publication number
- ATE496901T1 ATE496901T1 AT04752828T AT04752828T ATE496901T1 AT E496901 T1 ATE496901 T1 AT E496901T1 AT 04752828 T AT04752828 T AT 04752828T AT 04752828 T AT04752828 T AT 04752828T AT E496901 T1 ATE496901 T1 AT E496901T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- tetrahydrocannabinol
- delta
- cannabinoid derivatives
- cannabinoid
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 2
- 239000003557 cannabinoid Substances 0.000 title abstract 2
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 abstract 4
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 abstract 4
- 102000008906 Cannabinoid receptor type 2 Human genes 0.000 abstract 4
- 108050000860 Cannabinoid receptor type 2 Proteins 0.000 abstract 4
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 abstract 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical class C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 abstract 1
- 229960004242 dronabinol Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47231603P | 2003-05-20 | 2003-05-20 | |
| PCT/US2004/015885 WO2004113320A1 (en) | 2003-05-20 | 2004-05-20 | Cannabinoid derivatives, methods of making, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496901T1 true ATE496901T1 (de) | 2011-02-15 |
Family
ID=33539041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04752828T ATE496901T1 (de) | 2003-05-20 | 2004-05-20 | Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7169942B2 (https=) |
| EP (1) | EP1633733B1 (https=) |
| JP (1) | JP2007501279A (https=) |
| CN (1) | CN1809552A (https=) |
| AT (1) | ATE496901T1 (https=) |
| AU (1) | AU2004249669B2 (https=) |
| CA (1) | CA2526103A1 (https=) |
| DE (1) | DE602004031221D1 (https=) |
| DK (1) | DK1633733T3 (https=) |
| WO (1) | WO2004113320A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1727900A4 (en) * | 2004-03-26 | 2008-05-28 | Fujifilm Corp | METHOD FOR SELECTIVELY SEPARATING AND CLEANING RNA, AND METHOD FOR SEPARATING AND CLEANING NUCLEIC ACID |
| US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| USRE46558E1 (en) | 2005-04-28 | 2017-09-26 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| CN102766128A (zh) * | 2005-09-29 | 2012-11-07 | 阿尔巴尼分子研究公司 | δ-9-四氢大麻酚的生成方法 |
| DE102005062098A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Oxaphenanthren-Derivate |
| BRPI0708318A2 (pt) * | 2006-02-28 | 2011-05-24 | Paloma Pharmaceuticals, Inc. | composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese |
| WO2008109027A2 (en) | 2007-03-02 | 2008-09-12 | University Of Tennessee Research Foundation, The | Tri-aryl/heteroaroaromatic cannabinoids and use thereof |
| US20110021618A1 (en) * | 2008-03-25 | 2011-01-27 | Paloma Pharmaceuticals, Inc. | Methods of treating fibrotic disorders |
| JP2011520972A (ja) * | 2008-05-19 | 2011-07-21 | ユニヴァーシティ オブ テネシー リサーチ ファウンデーション，ザ | ピリジンの古典的カンナビノイド化合物及び関連する使用方法 |
| US8158654B2 (en) | 2008-05-19 | 2012-04-17 | The University Of Tennessee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| US8022078B2 (en) * | 2008-05-19 | 2011-09-20 | University Of Tennessee Research Foundation | Pyrimidine classical cannabinoid compounds and related methods of use |
| US8476439B2 (en) | 2008-05-19 | 2013-07-02 | The University Of Tennessee Research Foundation | Pyridine classical cannabinoid compounds and related methods of use |
| WO2009143183A1 (en) * | 2008-05-19 | 2009-11-26 | University Of Tennessee Research Foundation, The | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US8349876B2 (en) * | 2008-05-19 | 2013-01-08 | The University Of Tennesee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| US8389534B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US9623000B2 (en) | 2008-07-31 | 2017-04-18 | Dekel Pharmaceuticals Ltd | Compositions and methods for treating inflammatory disorders |
| WO2012112791A1 (en) | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| CN103110582A (zh) * | 2013-03-04 | 2013-05-22 | 上海医药工业研究院 | 大麻酚类化合物微乳剂及其制备方法 |
| US10610512B2 (en) | 2014-06-26 | 2020-04-07 | Island Breeze Systems Ca, Llc | MDI related products and methods of use |
| US20170008869A1 (en) * | 2015-07-10 | 2017-01-12 | Noramco, Inc. | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol |
| IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| US20180169061A1 (en) * | 2016-12-15 | 2018-06-21 | Ascent Pharmaceuticals, Inc. | Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations |
| WO2019045994A1 (en) * | 2017-08-27 | 2019-03-07 | Rhodes Technologies | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| WO2020041322A1 (en) | 2018-08-20 | 2020-02-27 | Berkowitz Barry A | Novel cannabinoids and cannabinoid acids and their derivatives |
| CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| CN110269839A (zh) * | 2019-06-15 | 2019-09-24 | 云南飞久逍科技有限公司 | 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用 |
| JP7770688B2 (ja) * | 2019-10-03 | 2025-11-17 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | リポソームカンナビノイドおよびその使用 |
| AU2020377914A1 (en) | 2019-11-08 | 2022-06-02 | Vella Bioscience, Inc. | Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941782A (en) * | 1972-04-27 | 1976-03-02 | Sharps Associates | Heterocyclic esters of benzopyrans |
| US3915996A (en) * | 1972-10-16 | 1975-10-28 | Abbott Lab | Process for making benzopyrans |
| US3901926A (en) * | 1973-04-02 | 1975-08-26 | Abbott Lab | Alkylphenyl benzopyrans |
| DE4100441A1 (de) * | 1991-01-09 | 1992-07-16 | Mack Chem Pharm | Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol |
| US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| DE69822449T2 (de) * | 1997-01-21 | 2005-01-27 | Smithkline Beecham Corp. | Neue cannabinoidrezeptor-modulatoren |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| DE19706903A1 (de) * | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
| EP0979228A4 (en) * | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| US5939429A (en) * | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
| WO1999057106A1 (en) * | 1998-05-04 | 1999-11-11 | The University Of Connecticut | Novel analgesic and immunomodulatory cannabinoids |
| US6563009B1 (en) * | 1999-07-12 | 2003-05-13 | Virginia Commonwealth University | Vasodilator cannabinoid analogs |
| FR2799124B1 (fr) * | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| IL132661A (en) * | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
| FR2804604B1 (fr) * | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| US20040039048A1 (en) * | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
| WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US6448288B1 (en) * | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| EP1299374B1 (en) * | 2000-06-22 | 2006-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| RU2004117907A (ru) * | 2001-11-14 | 2006-01-10 | Шеринг Корпорейшн (US) | Лиганды каннабиноидных рецепторов |
| MXPA04012704A (es) * | 2002-06-19 | 2005-03-23 | Schering Corp | Agonistas de los receptores canabinoides. |
| AU2003267728A1 (en) * | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
-
2004
- 2004-05-20 US US10/850,588 patent/US7169942B2/en not_active Expired - Fee Related
- 2004-05-20 WO PCT/US2004/015885 patent/WO2004113320A1/en not_active Ceased
- 2004-05-20 DE DE602004031221T patent/DE602004031221D1/de not_active Expired - Lifetime
- 2004-05-20 DK DK04752828.6T patent/DK1633733T3/da active
- 2004-05-20 AT AT04752828T patent/ATE496901T1/de not_active IP Right Cessation
- 2004-05-20 CN CNA2004800174008A patent/CN1809552A/zh active Pending
- 2004-05-20 CA CA002526103A patent/CA2526103A1/en not_active Abandoned
- 2004-05-20 EP EP04752828A patent/EP1633733B1/en not_active Expired - Lifetime
- 2004-05-20 JP JP2006533257A patent/JP2007501279A/ja active Pending
- 2004-05-20 AU AU2004249669A patent/AU2004249669B2/en not_active Ceased
-
2007
- 2007-01-26 US US11/698,665 patent/US20070167514A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1633733A4 (en) | 2007-02-28 |
| CN1809552A (zh) | 2006-07-26 |
| US20040242593A1 (en) | 2004-12-02 |
| WO2004113320A1 (en) | 2004-12-29 |
| EP1633733B1 (en) | 2011-01-26 |
| US7169942B2 (en) | 2007-01-30 |
| JP2007501279A (ja) | 2007-01-25 |
| AU2004249669B2 (en) | 2008-05-22 |
| DK1633733T3 (da) | 2011-05-16 |
| DE602004031221D1 (de) | 2011-03-10 |
| US20070167514A1 (en) | 2007-07-19 |
| EP1633733A1 (en) | 2006-03-15 |
| AU2004249669A1 (en) | 2004-12-29 |
| CA2526103A1 (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE496901T1 (de) | Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung | |
| NO20010446L (no) | Substituert anilidforbindelser og metoder | |
| ATE338565T1 (de) | Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm) | |
| ATE365165T1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| TR199801348T2 (xx) | Heterosikl-kondanse morfinoid t�revleri(II). | |
| DE69737592D1 (de) | Mittel gegen juckreiz | |
| EA199700156A1 (ru) | Производные индола как антагонисты рецептора 5-нт | |
| ATE272631T1 (de) | Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung | |
| BR0015962A (pt) | Compostos tendo ligações multiplas que são agonistas de receptor adrenérgico (beta)2 úteis no tratamento e prevenção de doenças respiratórias | |
| DK0901374T3 (da) | Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser | |
| BR9914526A (pt) | Derivados de adenina | |
| DE50106600D1 (de) | Verwendung von hydrophil modifizierten polyisocyanaten und polyurethanen als antiknitteradditiv für den heimbereich | |
| ATE234322T1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
| ATE473294T1 (de) | Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor | |
| ATE239823T1 (de) | Verffahren und vorrichtung zur steuerung der papiereigenschaften | |
| HUP0100621A2 (hu) | Monoamin oxidáz inhibitor hatású vegyületek és h5-HT1B antagonista vagy részleges agonista hatású vegyületek kombinációját tartalmazó gyógyászati készítmények | |
| AU5614198A (en) | Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors | |
| ATE227760T1 (de) | Mit nanopartikeln modifizierte bindemittel für überzugsmittel und deren verwendung | |
| DE60103856D1 (de) | Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität | |
| BR0307903A (pt) | derivados de arilsulfona | |
| DE60138808D1 (de) | G-protein gekoppelte rezeptoren | |
| ATE519762T1 (de) | Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung | |
| DE69633131D1 (de) | Rezeptor des y-y5 neuropeptids | |
| DE50209113D1 (de) | 1-allyl-ergotalkaloid-derivate- verfahren zu ihrer herstellung und ihre verwendung zur prophylaxe und therapie von migräne | |
| BRPI0520579A2 (pt) | composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |